LMAT Stock Analysis
LM
Avoid
Based on Eyestock quantitative analysis, LMAT`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
High score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Greatly overvalued
LeMaitre Vascular, Inc. engages in the provision of medical devices and human tissue cryopreservation services. The company is headquartered in Burlington, Massachusetts and currently employs 591 full-time employees. The company went IPO on 2006-10-19. The firm develops, manufactures and markets vascular devices to address the needs of vascular surgeons, and to a lesser degree, other specialties, such as cardiac surgeons, general surgeons and neurosurgeons. The Company’s product offerings are sold globally, primarily in the United States, Europe, Canada and Asia Pacific. Its products and services include Allografts, Angioscopes, Balloon Catheters for Embolectomy and Thrombectomy, Balloon Catheters for Occlusion and Perfusion, Bovine Grafts, Vascular and Cardiac Patches, Carotid Shunts, Closure Systems, Ovine Vascular Grafts, Polyester Vascular Grafts, ePTFE Vascular Grafts Radiopaque Tape, and Valvulotomes. Its PeriVu Disposable Angioscope is a fiberoptic catheter used for viewing the lumen of a blood vessel.